SCHEMBL6726545

SCHEMBL6726545

O=C(c1cnc(-c2ccccn2)nc1)N1CCN(S(=O)(=O)c2nc3ccc(Cl)cc3[nH]2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.46
METAP1 P53582 1/20 0.46
CBFB Q13951 1/20 0.46
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HRH4 Q9H3N8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
ALDH1A1 P00352 3/20 0.43
PKM P14618 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
F10 P00742 4/20 0.43
GRM5 P41594 3/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726550 0.93 LMNA (0.45) LMNAL3MBTL1ALDH1A1PKMRXFP1
SCHEMBL6737767 0.90 METAP2 (0.43) METAP2METAP1CBFBLMNAL3MBTL1
SCHEMBL6782078 0.89 HTR2B (0.53) METAP2METAP1CBFBHRH4HRH3
SCHEMBL6730495 0.89 HRH4 (0.44) LMNAL3MBTL1HRH4HRH3F10
SCHEMBL6726628 0.87 HRH4 (0.41) LMNAL3MBTL1HRH4HRH3ALDH1A1
SCHEMBL6730408 0.87 METAP2 (0.45) METAP2METAP1CBFBLMNAL3MBTL1
SCHEMBL6730938 0.87 F10 (0.41) LMNAL3MBTL1HRH4HRH3ALDH1A1
SCHEMBL6734491 0.86 ALDH1A1 (0.46) LMNAL3MBTL1HRH4HRH3ALDH1A1
SCHEMBL6729562 0.86 HTR2B (0.52) METAP2METAP1CBFBHRH4HRH3
SCHEMBL6730054 0.86 METAP2 (0.44) METAP2METAP1CBFBLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 METAP2 3629/4885METAP1 3239/4885CBFB 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.